Helpful Information

Benefits of Urgent Care Centers

We have partnered with CareWell, an urgent care center (UCC). You can go to CareWell and most UCCs for non-life-threatening injuries instead of going to the emergency room (ER). CareWell is an alternative to a primary care visit, especially if you need care after your primary care provider's office hours.

The benefits of a UCC are:

  • Shorter wait time
  • Less expensive than an ER visit (it typically costs the same as a primary care visit)
  • No appointments needed

Before going to a UCC, you should contact your primary care provider to find out your best option. To find UCCs in our provider network, use our Find a Doctor, Hospital or Pharmacy tool.


Community Partners Program

Helping members feel their best

If you’re coping with complex health issues, you may be eligible for a new level of support in your community. MassHealth launched the Community Partners (CP) program on July 1, 2018. The program helps eligible members with significant disabilities and behavioral health needs (mental health and/or substance use).

Streamlined care

CPs work with eligible members to:

  • Coordinate services
  • Enhance continuity and quality of care
  • Address the social factors that affect members’ health
  • Improve health outcomes
  • Help members live independently
  • Access community supports

What to expect

MassHealth chooses members for the program and refers them to CPs. Members can also be referred by their PCPs or other community providers. If you are referred, a CP will contact you. You can then choose whether to enroll in the program.

CPs are in your community

CPs are health care and human service organizations. They are based in the community. Behavioral health CPs provide services to adults with complex behavioral health needs. Long-term services and supports CPs help members (ages 3 to 64 with disabilities) get community and home­-based services.

For more information, call MassHealth at 800.841.2900 (TTY: 800.497.4648), Monday through Friday, from 8 a.m. to 5 p.m.


Follow Prescriber’s Instruction on Antidepressant Meds

Antidepressant medications are used to help treat depression and other mood disorders. For antidepressant medications to work properly, it is important to follow your prescriber’s instructions, to work with your prescriber to find the right medicine and dose that works for you and to take it until advised by your prescriber to stop. If you have been prescribed an antidepressant, follow these important guidelines to get better results:

 
  • Take antidepressant medication as prescribed (the amount, frequency and duration).
  • Try not to skip a dose. If you do miss a dose, take the next pill as scheduled; try not to “make-up” missed doses. Check with your prescriber or pharmacist to understand what to do if you regularly miss doses of your medication.
  • Do not stop taking antidepressants without checking with your provider first.
  • It may take up to four to six weeks for antidepressants to provide a noticeable difference.
  • You may get side effects from this medication. If you get side effects that cause you problems, don’t hesitate to talk with your prescriber who will work with you on an alternative plan.
  • You may get withdrawal symptoms when you stop taking antidepressant medications abruptly. You should talk to your prescriber about when and how to stop taking them when you feel ready.
  • Continue to take this medication even if you are feeling better, because stopping too soon may cause a relapse in your progress.
  • Contact your provider if you have any questions or concerns about your medication, including whether is working.
  • Be sure to make and keep all follow-up appointments.
  • If you think your medication is not working, talk to your prescriber about changing the dose, switching medication or adding a medication that may be a better choice for you.

For more information about depression, see this reference:

For more information regarding resources for depression or questions about coverage, you can call us at 888.257.1985 (TTY: 711), Monday through Friday, from 8 a.m. to 5 p.m.


The Importance of Behavioral Health Screenings

Early and regular health screenings are necessary to stay healthy at any age, but they are especially important for children, who are growing rapidly and expected to achieve particular milestones with age.

Stay healthy. Get screened.

When problems are caught early, for the most part they are easier to address and can prevent problems from getting bigger. Health screenings are all part of routine preventive care. These include many types of screenings, such as developmental, vision, hearing, dental, behavioral health and others. These screenings can jumpstart early treatment if necessary. Providers have a schedule they follow and know when each type of screening should be done. 

What to expect during your office visit

Specifically for a behavioral health screening, you can expect that when you bring your child or adolescent for an office visit, you will be asked to fill out a survey about your child’s:

  • Sleep
  • Energy 
  • Appetite 
  • School performance 
  • Ability to make friends 
  • Mood 
  • Behavior 

Adolescents may be asked to complete a similar survey about themselves. This is all part of a routine behavioral health screening. 

Providers will use a survey that is appropriate for your child’s age. The survey will come from a list of MassHealth-approved, standardized behavioral health screening tools. These tools can be helpful in highlighting areas you may be concerned about. They can make it easier to talk to your provider about your concerns and what you can do. 

Providers may discuss developmental expectations, give reassurance and even give common, effective parenting techniques that may help address your concerns.  

During time with your adolescent, your provider may discuss:

  • Avoiding the use of alcohol, drugs, tobacco and other substances that can lead to abuse
  • Violence
  • Bullying 
  • Depression 

If there is a need for further assessment in the area of behavioral health, your provider can offer the necessary behavioral health services or help refer you to another behavioral health specialist in your network.

Regular screenings, including a behavioral health screening, are important at any age but especially in growing children and teens learning coping strategies for new developmental challenges. If your provider does not offer a behavioral health screening, don’t hesitate to ask about it. Share any concerns you have about your child’s development, including problems with mood and behavior. 

Your provider is eager to help and find ways to keep your child on track and healthy for life.


When to Change from a Pediatrician to an Adult PCP

If you recently turned 19, you may need or want to transition your care from a pediatrician to a primary care provider (PCP) for adults (such as a general practitioner). You may need to choose a PCP for adults for the following reasons:

  • You have reached the age of 19
  • You are pregnant and want to have an adult PCP or obstetric gynecologist provide your care
  • Your pediatrician suggests you transition to a PCP for adults

We're here to help you make that transition. To change your pediatrician to an adult PCP, use our online Find a Doctor, Hospital or Pharmacy tool. Once you've selected a new PCP, you can log in to Tufts Health Member Connect to make the change in our system. Or you can call member services at 888.257.1985 (TTY: 711), Monday through Friday, from 8 a.m. to 5 p.m., for help finding a new PCP and/or changing your PCP.


Recent Vountary Drug Recalls


Ranitidine Capsules, Tablets and Oral Solution

Ranitidine Capsules, Tablets and Oral Solution

On October 23, and November 12, 2019, Amneal Pharmaceuticals, LLC., Aurobindo Pharma USA, Inc., Dr. Reddy’s Laboratories Ltd., Lannett Company, Inc., and Novitium Pharma, manufacturers of ranitidine, issued a voluntary recall of ranitidine capsules, oral solution and tablets. This recall was issued because an unexpected impurity was found in these products that may cause health risks.
 

What do you need to do?

  • Do not stop taking your medication without speaking with your doctor. The U.S. Food and Drug Administration (FDA) recommends that patients continue taking their medication, as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment.
  • Please call your doctor right away to obtain a new prescription for another appropriate medication. Your doctor will be able to prescribe another medication for you so you can continue treating your condition without interruption.

For more information or to report any adverse events or quality problems experienced with the use of this product directly to Dr. Reddy’s Laboratories Ltd., Lannett Company, Inc., Novitium Pharma., or you can report to the FDA's MedWatch Program.


Dr. Reddy’s Laboratories Ltd Voluntarily Recalled Products:

Description

Strength

Type

Pack

NDC
(National Drug Codes)

Ranitidine Capsules

150 mg

Rx

60 count bottle

5511112960

Ranitidine Capsules

150 mg

Rx

500 count bottle

5511112905

Ranitidine Capsules

300 mg

Rx

30 count bottle

5511113030

Ranitidine Capsules

300 mg

Rx

100 count bottle

5511113001

Ranitidine Tablets, USP (Sam’s Club)

150 mg

OTC

190 count (2x95) tray

150062076

Ranitidine Tablets, USP (Walgreens)

150 mg

OTC

95 count bottle

0363-0010-62

Ranitidine Tablets, USP (Walmart)

150 mg

OTC

220 count bottle

49035-404-65

Ranitidine Tablets, USP (Kroger)

150 mg

OTC

50 count bottle

30142-505-50

Ranitidine Tablets, USP (Kroger)

150 mg

OTC

24 count bottle

30142-505-34

Ranitidine Tablets, USP (Walgreens)

150 mg

OTC

65 count bottle

0363-0010-61

Ranitidine Tablets, USP CP32 (Walmart)

150 mg

OTC

65 count bottle

49035-404-61

Ranitidine Tablets, USP (Walgreens)

150 mg

OTC

200 count bottle

0363-0010-01

Ranitidine Tablets, USP (Walgreens)

150 mg

OTC

24 count bottle

0363-0010-34

Ranitidine Tablets, USP NG (CVS)

75 mg

OTC

30 count bottle

69842-871-30

Ranitidine Tablets, USP (Walgreens)

75 mg

OTC

30 count bottle

0363-0131-30

Ranitidine Tablets, USP (Walgreens)

75 mg

OTC

80 count bottle

0363-0131-80

Ranitidine Tablets, USP NG (CVS)

75 mg

OTC

80 count bottle

69842-871-80

Ranitidine Tablets, USP NG (CVS)

75 mg

OTC

160 count bottle

69842-871-37

Ranitidine Tablets, USP (Kroger)

75 mg

OTC

30 count bottle

30142-131-30

Ranitidine Tablets, USP (CDMA)

150 mg

OTC

24 count bottle

63868-480-24

Ranitidine Tablets, USP NV (Walmart)

150 mg

OTC

130 count bottle

49035-404-13

Ranitidine Tablets, USP (CDMA)

150 mg

OTC

50 count bottle

63868-480-50

Ranitidine Tablets, USP (Dr. Reddy’s)

75 mg

OTC

60 count bottle

55111-131-60

Ranitidine Tablets, USP (CDMA)

75 mg

OTC

60 count bottle

63868-482-60

Ranitidine Tablets, USP (CDMA)

75 mg

OTC

30 count bottle

63868-482-30

Ranitidine Tablets, USP (Dr. Reddy’s)

150 mg

OTC

24 count bottle

55111-404-34

Ranitidine Tablets, USP (HCA)

150 mg

OTC

95 count bottle

43598-808-62

Ranitidine Tablets, USP (HCA)

150 mg

OTC

220 count bottle

43598-808-65

Ranitidine Tablets, USP (Target)

150 mg

OTC

40 count bottle

11673-849-40

Ranitidine Tablets, USP (Thirty Madison)

150 mg

OTC

24 count bottle

71713-203-02

Ranitidine Tablets, USP (Thirty Madison)

150 mg

OTC

95 count bottle

71713-203-05

Ranitidine Tablets, USP (GeriCare)

75 mg

OTC

All counts

57896-715

Ranitidine Tablets, USP (GeriCare)

150 mg

OTC

All counts

57896-717

​Lannett Company, Inc. Voluntarily Recalled Ranitidine Syrup (oral solution) 15mg/mL:

NDC Code

Batch

Expiration Date (Month/Year)

NDC Code

Batch

Expiration Date (Month/Year)

54838-550-80

1503A

Oct./2019

54838-550-80

1646A

Feb./2020

54838-550-80

1504A

Oct./2019

54838-550-80

1647A

Feb./2020

54838-550-80

1505A

Oct./2019

54838-550-80

1668A

Mar./2020

54838-550-80

1523A

Oct./2019

54838-550-80

1669A

Mar./2020

54838-550-80

1524A

Oct./2019

54838-550-80

1670A

Mar./2020

54838-550-80

1525A

Nov./2019

54838-550-80

1708A

Mar./2020

54838-550-80

1561A

Dec./2019

54838-550-80

1709A

Apr./2020

54838-550-80

1562A

Dec./2019

54838-550-80

1710A

Apr./2020

54838-550-80

1563A

Dec./2019

54838-550-80

1729A

Apr./2020

54838-550-80

1589A

Dec./2019

54838-550-80

1730A

Apr./2020

54838-550-80

1590A

Dec./2019

54838-550-80

1731A

Apr./2020

54838-550-80

1591A

Dec./2019

54838-550-80

1757A

May./2020

54838-550-80

1614A

Jan./2020

54838-550-80

1758A

May./2020

54838-550-80

1615A

Jan./2020

54838-550-80

1759A

May./2020

54838-550-80

1617A

Jan./2020

54838-550-80

1773A

Jun./2020

54838-550-80

1644A

Feb./2020

54838-550-80

1774A

Jun./2020

54838-550-80

1775A

Jun./2020

54838-550-80

1989A

Dec./2020

54838-550-80

1794A

Jun./2020

54838-550-80

1990A

Dec./2020

54838-550-80

1795A

Jun./2020

54838-550-80

1991A

Dec./2020

54838-550-80

1796A

Jun./2020

54838-550-80

1998A

Jan./2021

54838-550-80

1817A

Jun./2020

54838-550-80

1999A

Jan./2021

54838-550-80

1818A

Jul./2020

54838-550-80

2000A

Jan./2021

54838-550-80

1819A

Jul./2020

54838-550-80

2019A

Jan./2021

54838-550-80

1840A

Aug./2020

54838-550-80

2020A

Jan./2021

54838-550-80

1840B

Aug./2020

54838-550-80

2065A

Mar./2021

54838-550-80

1841A

Aug./2020

54838-550-80

2066A

Mar./2021

54838-550-80

1842A

Aug./2020

54838-550-80

2067A

Mar./2021

54838-550-80

1863A

Aug./2020

54838-550-80

2071A

Mar./2021

54838-550-80

1864A

Sep./2020

54838-550-80

2072A

Mar./2021

54838-550-80

1865A

Sep./2020

54838-550-80

2073A

Mar./2021

54838-550-80

1899A

Oct./2020

54838-550-80

2076A

Mar./2021

54838-550-80

1900A

Oct./2020

54838-550-80

2077A

Mar./2021

54838-550-80

1901A

Oct./2020

54838-550-80

2078A

Mar./2021

54838-550-80

1910A

Oct./2020

54838-550-80

2126A

May./2021

54838-550-80

1911A

Oct./2020

54838-550-80

2127A

May./2021

54838-550-80

1912A

Oct./2020

54838-550-80

2128A

May./2021

54838-550-80

1918A

Oct./2020

54838-550-80

2164A

Jun./2021

54838-550-80

1919A

Oct./2020

54838-550-80

2165A

Jun./2021

54838-550-80

1920A

Oct./2020

54838-550-80

2166A

Jun./2021

54838-550-80

1925A

Oct./2020

54838-550-80

2179A

Jun./2021

54838-550-80

1926A

Oct./2020

54838-550-80

2180A

Jul./2021

54838-550-80

1927A

Oct./2020

54838-550-80

2181A

Jul./2021

54838-550-80

1977A

Dec./2020

54838-550-80

2214A

Aug./2021

54838-550-80

1978A

Dec./2020

54838-550-80

2215A

Aug./2021

54838-550-80

1979A

Dec./2020

54838-550-80

2216A

Aug./2021

Novitium Pharma Voluntarily Recalled Products:

Description

Strength

Type

Pack Size

NDC

Ranitidine Capsules

150 mg

Rx

60 count bottle

70954-001-20

Ranitidine Capsules

150 mg

Rx

500 count bottle

70954-001-40

Ranitidine Capsules

300 mg

Rx

30 count bottle

70954-002-10

Ranitidine Capsules

300 mg

Rx

100 count bottle

70954-002-40

Amneal Pharmaceuticals, LLC. Voluntarily Recalled Products:

Product

Strength

NDC Number

Ranitidine Tablets, USP

150 mg

65162-253-06

Ranitidine Tablets, USP

150 mg

65162-253-10

Ranitidine Tablets, USP

150 mg

65162-253-18

Ranitidine Tablets, USP

150 mg

65162-253-50

Ranitidine Tablets, USP

150 mg

65162-253-11

Ranitidine Tablets, USP

300 mg

65162-254-03

Ranitidine Tablets, USP

300 mg

65162-254-10

Ranitidine Tablets, USP

300 mg

65162-254-25

Ranitidine Tablets, USP

300 mg

65162-254-11

Ranitidine Tablets, USP

150 mg

53746-253-05

Ranitidine Tablets, USP

150 mg

53746-253-10

Ranitidine Syrup (Ranitidine Oral Solution, USP)

15 mg/mL; 16 fl. oz.

65162-664-90

Aurobindo Pharma USA, Inc. Voluntarily Recalled Products:

Product Name

NDC

Exp. Date

Ranitidine Tablets 150mg

55910-092-79

Feb-21

Ranitidine Capsules 150mg

59651-144-60

Jul-20

Jul-20

59651-144-05

Jul-20

Jul-20

Aug-20

Aug-20

59651-144-60

Aug-20

Aug-20

59651-144-05

Sep-20

Sep-20

Sep-20

Oct-20

Nov-20

Nov-20

Nov-20

Nov-20

Nov-20

59651-144-60

May-21

59651-144-05

May-21

May-21

Ranitidine Capsules 300mg

59651-145-30

Jul-20

Jul-20

Jul-20

Aug-20

Aug-20

Aug-20

Sep-20

Sep-20

Sep-20

Oct-20

Jan-21

Jan-21

May-21

Ranitidine Syrup (Ranitidine Oral Solution, USP) 15 mg/mL (75 mg/5 mL)

65862-431-74

May-21

May-21

May-21

May-21


NATPARA® (parathyroid hormone) for Injection

On September 5, 2019 Takeda Pharmaceutical Company Limited, manufacturer of NATPARA® (parathyroid hormone) for Injection, issued a voluntary recall of all lots of this product. This recall was issued because of the potential risk of rubber particles in the cartridge. Small pieces of rubber may break off when the rubber septum is punctured multiple times for repeated doses.

Affected NDCs

Product Name

NDC #

Lot #

NATPARA® (Parathyroid Hormone) for Injection 25 mcg

68875-0202-01
68875-0202-02

All

NATPARA® (Parathyroid Hormone) for Injection 50 mcg

68875-0203-01
68875-0203-02

All

NATPARA® (Parathyroid Hormone) for Injection 75 mcg

68875-0204-01
68875-0204-02

All

NATPARA® (Parathyroid Hormone) for Injection 100 mcg

68875-0205-01
68875-0205-02

All

 

What do you need to do?

  • Do not stop taking your medication without speaking with your doctor. The U.S. Food and Drug Administration (FDA) recommends that patients continue taking their medication, because of the potential risk of harm to a patient's health if the treatment is stopped immediately without any alternative treatment.
  • Please call your doctor right away to obtain a new prescription for another appropriate medication. Your doctor will be able to prescribe another medication for you so you can continue treating your condition without interruption

For more information

For more information, if you have not already been contacted by Takeda or to report any adverse events or quality problems experienced with the use of this product, contact Takeda Pharmaceuticals Limited toll free at 1.866.888.0660 or visit www.takeda.com. You can also report this to the FDA's MedWatch Program.

To report an adverse event to the FDA Med Watch Program: